Small-molecule perturbation of competing interactions between c-Myc and Max
Abstract
The oncogenic transcription factor c-Myc undergoes coupled binding and folding of its basic-helix-loop-helix-leucine zipper domain (bHLHZip) upon heterodimerization with its partner protein Max. The latter exists in two isoforms: p21, which homodimerizes poorly, and p22, which homodimerizes well. We show that the effect of 10058-F4 (a small-molecule that binds disordered c-Myc monomers and disrupts the c-Myc-Max complex) on both c-Myc-Max heterodimerization and DNA binding is dependent on the nature of the Max isoform. In the presence of p22 Max the effective inhibitor concentration is lower than in the presence of p21 Max, as the p22 Max homodimer formation affects the thermodynamics by competing against the c-Myc-Max heterodimerization event.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The c-Myc inhibitor 10058-F4 prevents the c-Myc-Max interaction and inhibits transcription of c-Myc target gene expression.
“To monitor the effect of inhibiting c-Myc activity we administered the specific c-Myc inhibitor, 10058-F4, which prevents the c-Myc-Max interaction and inhibits transcription of c-Myc target gene expression32.”
From Blimp1+ cells generate functional mouse sebaceous gland organoids in vitro (2019) · cites this paper as [32]
Cites
Intrinsically unstructured proteins and their functions
Dyson, H. J., & Wright, P. E. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1589 · Cited by 3,871 · see citing works
Towards a proteome-scale map of the human protein–protein interaction network
Rual, J.-F. M., Venkatesan, K., Hao, T., Hirozane-Kishikawa, T., Dricot, A., Li, N., Berriz, G. F., Gibbons, F. D., Dreze, M., Ayivi-Guedehoussou, N., et al. (2005) · Nature · doi:10.1038/nature04209 · Cited by 2,904 · see citing works
Evidence for dynamically organized modularity in the yeast protein–protein interaction network
Han, J. J., Bertin, N., Hao, T., Goldberg, D. S., Berriz, G. F., Zhang, L. V., Dupuy, D., Walhout, A. J. M., Cusick, M. E., Roth, F. P., et al. (2004) · Nature · doi:10.1038/nature02555 · Cited by 1,789 · see citing works
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,707 · see citing works
Transcription factors: structural families and principles of DNA recognition.
Pabo, C., & Sauer, R. (1992) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.61.070192.005201 · Cited by 1,445 · see citing works
Coupling of folding and binding for unstructured proteins
Dyson, H. J., & Wright, P. E. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00289-0 · Cited by 1,327 · see citing works
Intrinsic Disorder in Cell-signaling and Cancer-associated Proteins
Iakoucheva, L. M., Brown, C. J., Lawson, J. D., Obradović, Z., & Dunker, A. K. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00969-5 · Cited by 1,214 · see citing works
Navigating chemical space for biology and medicine
Lipinski, C. A., & Hopkins, A. L. (2004) · Nature · doi:10.1038/nature03193 · Cited by 1,008 · see citing works
Modular organization of cellular networks
Rives, A. W., & Galitski, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237338100 · Cited by 695 · see citing works
X-Ray Structures of Myc-Max and Mad-Max Recognizing DNA
Nair, S. K., & Burley, S. K. (2003) · Cell · doi:10.1016/s0092-8674(02)01284-9 · Cited by 551 · see citing works
Structural disorder throws new light on moonlighting
Tompa, P., Szász, C., & Buday, L. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2005.07.008 · Cited by 468 · see citing works
Comprehensive Identification of Human bZIP Interactions with Coiled-Coil Arrays
Newman, J. R. S., & Keating, A. E. (2003) · Science · doi:10.1126/science.1084648 · Cited by 449 · see citing works
Low molecular weight inhibitors of Myc–Max interaction and function
Yin, X., Giap, C., Lazo, J. S., & Prochownik, E. V. (2003) · Oncogene · doi:10.1038/sj.onc.1206641 · Cited by 426 · see citing works
Berg, T., Cohen, S. B., Desharnais, J., Sonderegger, C. K., Maslyar, D. J., Goldberg, J., Boger, D. L., & Vogt, P. K. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.062036999 · Cited by 326 · see citing works
Helix-loop-helix proteins as regulators of muscle-specific transcription.
Edmondson, D. G., & Olson, E. N. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53995-8 · Cited by 273 · see citing works
Improved low molecular weight Myc-Max inhibitors
Wang, H., Hammoudeh, D. I., Follis, A. V., Reese, B. E., Lazo, J. S., Metallo, S. J., & Prochownik, E. V. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0005 · Cited by 191 · see citing works
Self-citationBrownlie, P. D., Ceska, T. A., Lamers, M. H., Romier, C., Stier, G., Teo, H., & Suck, D. (1997) · Structure · doi:10.1016/s0969-2126(97)00207-4 · Cited by 169 · see citing works
Visualization of Myc/Max/Mad Family Dimers and the Competition for Dimerization in Living Cells
Grinberg, A. V., Hu, C., & Kerppola, T. K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.10.4294-4308.2004 · Cited by 169 · see citing works
Cancer therapeutics: Targeting the dark side of Myc
Ponzielli, R., Katz, S., Baršytė-Lovejoy, D., & Penn, L. Z. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.017 · Cited by 166 · see citing works
Romero, P. R., Zoran Obradovic, A., & Dunker, A. K. (2004) · Applied Bioinformatics · doi:10.2165/00822942-200403020-00005 · Cited by 163 · see citing works
Selective Inhibition of c-Myc/Max Dimerization and DNA Binding by Small Molecules
Kiessling, A., Sperl, B., Hollis, A., Eick, D., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.05.011 · Cited by 148 · see citing works
Myc and Max function as a nucleoprotein complex
Blackwood, E. M., Kretzner, L., & Eisenman, R. N. (1992) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(05)80278-3 · Cited by 141 · see citing works
Transcriptional Repression in Eukaryotes
Herschbach, B. M., & Johnson, A. D. (1993) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.09.110193.002403 · Cited by 116 · see citing works
A credit-card library approach for disrupting protein–protein interactions
Xu, Y., Shi, J., Yamamoto, N., Moss, J. A., Vogt, P. K., & Janda, K. D. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.11.052 · Cited by 93 · see citing works
Bousset, K., Henriksson, M., Lüscher‐Firzlaff, J., Litchfield, D. W., & Lüscher, B. (1993) · PubMed · Cited by 79 · see citing works
Differential patterns of DNA binding by myc and max proteins.
Prochownik, E., & VanAntwerp, M. E. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.960 · Cited by 69 · see citing works
Hu, J., Banerjee, A., & Goss, D. J. (2005) · Biochemistry · doi:10.1021/bi050206i · Cited by 49 · see citing works
Distinct Roles for MAX Protein Isoforms in Proliferation and Apoptosis
Zhang, H., Fan, S., & Prochownik, E. V. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17416 · Cited by 48 · see citing works
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390 · see citing works
Understanding protein non-folding
Uversky, V. N., & Dunker, A. K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.01.017 · Cited by 1,188 · see citing works
Pathological Unfoldomics of Uncontrolled Chaos: Intrinsically Disordered Proteins and Human Diseases
Uversky, V. N., Davé, V., Iakoucheva, L. M., Malaney, P., Metallo, S. J., Pathak, R. R., & Joerger, A. C. (2014) · Chemical Reviews · doi:10.1021/cr400713r · Cited by 288 · see citing works
Self-citationSmall Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics
Chen, B.-J., Wu, Y., Tanaka, Y., & Zhang, W. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.10190 · Cited by 247 · see citing works
Elbadawy, M., Usui, T., Yamawaki, H., & Sasaki, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092340 · Cited by 237 · see citing works
A complex task? Direct modulation of transcription factors with small molecules
Koehler, A. N. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.022 · Cited by 189 · see citing works
Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence
Takeishi, S., Matsumoto, A., Onoyama, I., Naka, K., Hirao, A., & Nakayama, K. I. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.026 · Cited by 177 · see citing works
Expanding the proteome: disordered and alternatively folded proteins
Dyson, H. J. (2011) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583511000060 · Cited by 173 · see citing works
Small-molecule inhibitors of the Myc oncoprotein
Fletcher, S., & Prochownik, E. V. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.005 · Cited by 153 · see citing works
Carey, J. P. W., Karakaş, C., Bui, T. N., Chen, X., Vijayaraghavan, S., Zhao, Y., Wang, J., Mikule, K. W., Litton, J. K., Hunt, K. K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1494 · Cited by 145 · see citing works
Mission Possible: Advances in MYC Therapeutic Targeting in Cancer
Allen-Petersen, B. L., & Sears, R. C. (2019) · BioDrugs · doi:10.1007/s40259-019-00370-5 · Cited by 143 · see citing works
Uversky, V. N. (2010) · Expert Review of Proteomics · doi:10.1586/epr.10.36 · Cited by 141 · see citing works
Clausen, D. M., Guo, J., Parise, R. A., Beumer, J. H., Egorin, M. J., Lazo, J. S., Prochownik, E. V., & Eiseman, J. L. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.170555 · Cited by 117 · see citing works
Intrinsically disordered proteins and biomolecular condensates as drug targets
Biesaga, M., Frigolé-Vivas, M., & Salvatella, X. (2021) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2021.02.009 · Cited by 115 · see citing works
Mekonnen, N., Yang, H., & Shin, Y. K. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880643 · Cited by 113 · see citing works
Targeting intrinsically disordered proteins involved in cancer
Santofimia‐Castaño, P., Rizzuti, B., Xia, Y., Abián, O., Peng, L., Velázquez‐Campoy, A., Neira, J. L., & Iovanna, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03347-3 · Cited by 110 · see citing works
Beaulieu, M.-È., Castillo, F., & Soucek, L. (2020) · Cells · doi:10.3390/cells9041038 · Cited by 110 · see citing works
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 107 · see citing works
Targeting disordered proteins with small molecules using entropy
Heller, G. T., Sormanni, P., & Vendruscolo, M. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.07.004 · Cited by 104 · see citing works
Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
Müller, I., Larsson, K., Frenzel, A., Oliynyk, G., Zirath, H., Prochownik, E. V., Westwood, N. J., & Arsenian‐Henriksson, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097285 · Cited by 96 · see citing works
Pan, X.-N., Chen, J.-J., Wang, L.-X., Xiao, R.-Z., Liu, L.-L., Fang, Z.-G., Liu, Q., Long, Z., & Lin, D.-J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0105381 · Cited by 82 · see citing works
Michel, J., & Cuchillo, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041070 · Cited by 74 · see citing works
Sequence Specificity in the Entropy-Driven Binding of a Small Molecule and a Disordered Peptide
Heller, G. T., Aprile, F. A., Bonomi, M., Camilloni, C., Simone, A. D., & Vendruscolo, M. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.07.016 · Cited by 64 · see citing works
Methods of probing the interactions between small molecules and disordered proteins
Heller, G. T., Aprile, F. A., & Vendruscolo, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2563-4 · Cited by 62 · see citing works
RETRACTED: Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma
Feng, W., Dean, D. C., Hornicek, F. J., Spentzos, D., Hoffman, R. M., Shi, H., & Duan, Z. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922055 · Cited by 57 · see citing works
RetractedWang, H., Chauhan, J., Hu, A., Pendleton, K. P., Yap, J. L., Sabato, P. E., Jones, J. W., Perri, M., Yu, J., Cione, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1108 · Cited by 57 · see citing works
Prion-Like Proteins in Phase Separation and Their Link to Disease
Sprunger, M. L., & Jackrel, M. E. (2021) · Biomolecules · doi:10.3390/biom11071014 · Cited by 57 · see citing works
Intravesical Instillation of c-MYC Inhibitor KSI-3716 Suppresses Orthotopic Bladder Tumor Growth
Jeong, K., Kim, K., Seo, H.-H., Shin, S.-P., Ahn, K.-O., Ji, M.-J., Park, W. S., Kim, I.-H., Lee, S.-J., & Seo, H. K. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.07.019 · Cited by 55 · see citing works
Blimp1+ cells generate functional mouse sebaceous gland organoids in vitro
Feldman, A., Mukha, D., Maor, I. I., Sedov, E., Koren, E., Yosefzon, Y., Shlomi, T., & Fuchs, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-10261-6 · Cited by 52 · see citing works
Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletion
Wang, H., Sharma, L., Lu, J. L., Finch, P., Fletcher, S., & Prochownik, E. V. (2015) · Oncotarget · doi:10.18632/oncotarget.4327 · Cited by 41 · see citing works
Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth
Lustig, L. C., Dingar, D. D., Tu, W. B., Lourenco, C., Kalkat, M., Inamoto, I., Ponzielli, R., Chan, W. C. W., Shin, J. A., & Penn, L. Z. (2017) · Oncogene · doi:10.1038/onc.2017.275 · Cited by 41 · see citing works
Protein homodimer sequestration with small molecules: Focus on PD-L1
Bailly, C., & Vergoten, G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113821 · Cited by 38 · see citing works
MYC the oncogene from hell: Novel opportunities for cancer therapy
Papadimitropoulou, A., Makri, M., & Zoidis, G. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116194 · Cited by 38 · see citing works
Sammak, S., & Zinzalla, G. (2015) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2015.06.004 · Cited by 37 · see citing works
Mechanisms of small-molecule binding to intrinsically disordered proteins
Cuchillo, R., & Michel, J. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120086 · Cited by 36 · see citing works
Role of TGF-β signaling in uterine carcinosarcoma
Dwivedi, S. K. D., McMeekin, S., Slaughter, K. N., & Bhattacharya, R. (2015) · Oncotarget · doi:10.18632/oncotarget.3711 · Cited by 27 · see citing works
Mapping Hidden Residual Structure within the Myc bHLH-LZ Domain Using Chemical Denaturant Titration
Panova, S., Cliff, M. J., Macek, P., Blackledge, M. J., Jensen, M. R., Nissink, J. W. M., Embrey, K. J., Davies, R., & Waltho, J. P. (2019) · Structure · doi:10.1016/j.str.2019.07.006 · Cited by 23 · see citing works
c-Myc promotes cholangiocarcinoma cells to overcome contact inhibition via the mTOR pathway
Luo, G., Li, B., Duan, C., Cheng, Y., Xiao, B., Yao, F., Wei, M., Tao, Q., Feng, C., Xia, X., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5913 · Cited by 22 · see citing works
Wang, H., Ramakrishnan, A., Fletcher, S., & Prochownik, E. V. (2015) · Journal of Biological Methods · doi:10.14440/jbm.2015.54 · Cited by 20 · see citing works
Albanus, R. D., Dalmolin, R. J. S., Castro, M. A. A., Pasquali, M. A. D. B., Ramos, V. D. M., Gelain, D. P., & Moreira, J. C. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082457 · Cited by 14 · see citing works
Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification
Talapatra, J., & Reddy, M. M. (2023) · Cancers · doi:10.3390/cancers15072144 · Cited by 12 · see citing works
Multistage modeling of protein dynamics with monomeric Myc oncoprotein as an example
Liu, J., Dai, J., He, J., Niemi, A. J., & Ilieva, N. (2017) · Physical review. E · doi:10.1103/physreve.95.032406 · Cited by 8 · see citing works
Computational Strategies in Cancer Drug Discovery
Mustata, G. I., & Muftuoglu, Y. (2012) · InTech eBooks · doi:10.5772/24177 · Cited by 7 · see citing works
Kojima, M., Abe, S., Furuta, T., Hirata, K., Yao, X., Kobayashi, A., Kobayashi, R., & Ueno, T. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322452121 · Cited by 6 · see citing works
Innovative approaches in skin therapy: The rise of organoid cultivation
Zhou, R., Luo, X., Chen, S., Jia, K., Yu, H., Huang, Z., Tan, Y., Ma, M., Zhao, J., Xing, J., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.162248 · Cited by 6 · see citing works
Liu, Q., Nguyen, É., Døskeland, S. O., & Ségal-Bendirdjian, É. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.097915 · Cited by 6 · see citing works
Zhang, Y., Shao, Y., Lv, Z., Zhang, W., Zhao, X., Guo, M. Z., & Li, C. (2019) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2019.103487 · Cited by 6 · see citing works
Xu, L., Sun, Y., Li, W., Mai, L., Guo, Y., & Fan, Q.-X. (2014) · Oncology Research and Treatment · doi:10.1159/000360207 · Cited by 5 · see citing works
S146L in MYC is a context-dependent activating substitution in cancer development
Hinds, J. W., Feris, E. J., Wilkins, O. M., Deary, L. T., Wang, X., & Cole, M. D. (2022) · PLoS ONE · doi:10.1371/journal.pone.0272771 · Cited by 4 · see citing works
Targeting an Interaction Between Two Disordered Domains by Using a Designed Peptide
Mayer, G., Shpilt, Z., Bressler, S., Marcu, O., Schueler‐Furman, O., Tshuva, E. Y., & Friedler, A. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000465 · Cited by 4 · see citing works
A Hybrid G-Quadruplex Structure Formed by a Sequence from the MAX Gene
Hu, X., Xiao, N., Lan, W., & Cao, C. (2025) · JACS Au · doi:10.1021/jacsau.5c01247 · Cited by 3 · see citing works
Morphological inhibitors of aggregation-prone amyloid- β conformers: A computational exploration
Bosio, S., Falchi, F., Rauzi, C., & Bellucci, L. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110545 · Cited by 2 · see citing works
Fu, Y., Jiang, L., Xie, G., Peng, Y., Fu, Y., Zhu, Q., Liu, Y., Zhao, G., Liu, X., Peng, Y., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01744-3 · Cited by 2 · see citing works
Probing the Structural Dynamics of the Unbound MAX Protein: Insights from Well-Tempered Metadynamics
Lu, H., Marti, J., & Faraudo, J. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5c02155 · Cited by 1 · see citing works
Tesell, J. (2013) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2nc8v
Targeting MYC and Exploring the Role of Mitochondrial Metabolism in Childhood Neuroblastoma
Zirath, H. (2014) · Figshare
Müller, I. (2014) · Figshare
Tavakoli, I. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0072850
The Functions and Regulatory Chemicals of Human Leucine Zipper Transcription Factors (LZ TFs)
Yang, H., Bi, S., Yu, B., Fang, P., & Wang, J. (2025) · 化学学报 · doi:10.6023/a25020042
BindingDB Entry 50021153: MYC the oncogene from hell: Novel opportunities for cancer therapy.
BindingDB (2025) · UC San Diego · doi:10.7270/q2qz2gkz
- Authors
- Follis, A. V., Hammoudeh, D. I., Daab, A. T., & Metallo, S. J.
- Affiliations
- Georgetown University (US)
- Corresponding author
- Metallo, Steven J.
- ORCID
- Daab, Andrew T.
- Venue
- Bioorganic & Medicinal Chemistry Letters
- Publisher
- Elsevier BV
- Published
- 2009-02
- Volume
- 19
- Issue
- 3
- Pages
- 807-810
- ISSN
- 0960-894X (ISSN-L)
- OpenAlex
- W1986100580
- Cited by
- 60
- References
- 29
- Citations by year
- 2025: 7 · 2024: 2 · 2023: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2019: 6 · 2017: 6 · 2016: 1 · 2015: 6 · 2014: 8 · 2013: 6 · 2012: 4
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Bioorganic & Medicinal Chemistry Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Keywords
- c-Myc, Max, 10058-F4, small molecule inhibitors, protein heterodimerization, protein folding, protein-DNA interactions, protein-protein interaction, oncogenic transcription factor
- MeSH terms
- Binding Sites, Chemistry, Pharmaceutical, DNA, Humans, Kinetics, Models, Biological, Protein Binding, Thermodynamics, Drug Design, Proto-Oncogene Proteins c-myc, Protein Structure, Tertiary, Dimerization, Protein Isoforms, Basic-Leucine Zipper Transcription Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review